Literature DB >> 12417561

Modeling the benefits of pamidronate in children with osteogenesis imperfecta.

Robert Lindsay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12417561      PMCID： PMC151622          DOI： 10.1172/JCI17051

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  10 in total

1.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Authors:  J E Dunford; K Thompson; F P Coxon; S P Luckman; F M Hahn; C D Poulter; F H Ebetino; M J Rogers
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

2.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.

Authors:  Frank Rauch; Rose Travers; Horacio Plotkin; Francis H Glorieux
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.

Authors:  J M Halasy-Nagy; G A Rodan; A A Reszka
Journal:  Bone       Date:  2001-12       Impact factor: 4.398

4.  Type V osteogenesis imperfecta: a new form of brittle bone disease.

Authors:  F H Glorieux; F Rauch; H Plotkin; L Ward; R Travers; P Roughley; L Lalic; D F Glorieux; F Fassier; N J Bishop
Journal:  J Bone Miner Res       Date:  2000-09       Impact factor: 6.741

5.  Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

Authors:  Francis H Glorieux; Leanne M Ward; Frank Rauch; Ljiljana Lalic; Peter J Roughley; Rose Travers
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

6.  Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss.

Authors:  Y Duan; C H Turner; B T Kim; E Seeman
Journal:  J Bone Miner Res       Date:  2001-12       Impact factor: 6.741

7.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

8.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

9.  The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.

Authors:  J P Brown; D L Kendler; M R McClung; R D Emkey; J D Adachi; M A Bolognese; Z Li; A Balske; R Lindsay
Journal:  Calcif Tissue Int       Date:  2002-06-27       Impact factor: 4.333

10.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

Authors:  F H Glorieux; N J Bishop; H Plotkin; G Chabot; G Lanoue; R Travers
Journal:  N Engl J Med       Date:  1998-10-01       Impact factor: 91.245
  10 in total
  9 in total

1.  Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.

Authors:  Eva Aström; Håkan Jorulf; Stefan Söderhäll
Journal:  Arch Dis Child       Date:  2006-11-17       Impact factor: 3.791

2.  Conservative versus surgical treatment of osteogenesis imperfecta: a retrospective analysis of 29 patients.

Authors:  Eugenio Chiarello; Davide Donati; Giuseppe Tedesco; Luca Cevolani; Tommaso Frisoni; Matteo Cadossi; Martha Hoque; Benedetta Spazzoli; Sandro Giannini
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

3.  Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions.

Authors:  Fatih Suheyl Ezgu; Necla Buyan; Mehmet Gündüz; Leyla Tümer; Ilyas Okur; Alev Hasanoglu
Journal:  Eur J Pediatr       Date:  2004-01-09       Impact factor: 3.183

4.  Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.

Authors:  Jin-Ho Choi; Young-Lim Shin; Han-Wook Yoo
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

5.  Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.

Authors:  S H Rao; K D Evans; A M Oberbauer; R B Martin
Journal:  J Biomech       Date:  2008-11-20       Impact factor: 2.712

6.  Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study.

Authors:  Gelsomina L Borromeo; Caroline Brand; John G Clement; Michael McCullough; Wendy Thomson; Elly Flitzanis; John D Wark
Journal:  BMC Musculoskelet Disord       Date:  2011-04-10       Impact factor: 2.362

7.  Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta.

Authors:  F de Graaff; W Verra; J E H Pruijs; R J B Sakkers
Journal:  J Child Orthop       Date:  2011-01-25       Impact factor: 1.548

8.  The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta.

Authors:  Ingmar Ipach; Torsten Kluba; Petra Wolf; Bertram Pontz; Falk Mittag
Journal:  Orthop Rev (Pavia)       Date:  2012-09-04

9.  Parathyroid hormone-related protein inhibits nitrogen-containing bisphosphonate-induced apoptosis of human periodontal ligament fibroblasts by activating MKP1 phosphatase.

Authors:  Di Liu; Juan Du; Jing Sun; Minqi Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.